-
Company Profile
NewSymphogen A/S – Company Profile
Symphogen A/S (Symphogen) is a biopharmaceutical company that specializes in the field of recombinant antibody mixtures for therapeutic use in cancer. The company focuses on developing superior monoclonal antibody (mAb) mixture therapeutics. The product pipeline provides novel approaches to a wide range of cancer types including metastatic colorectal cancer (mCRC), solid tumor malignancies, and lung cancer. The company has collaborations for the development of antibody therapeutics in immuno-oncology with the Shire and infectious disease area with Genentech. It has offices...
Add to Basket -
Product Insights
Bile Duct Cancer (Cholangiocarcinoma) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Bile Duct Cancer Pipeline Drugs Market Report Overview Bile duct cancer (cholangiocarcinoma) are tumors that occur in the bile duct. Symptoms include discomfort in the tummy area (abdomen), loss of appetite, high temperatures (fevers), and weight loss. Treatment includes chemotherapy and radiation therapy. The Bile Duct Cancer drugs in development market research report provides comprehensive information on the therapeutics under development for Bile Duct Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of...
-
Product Insights
Non-Small Cell Lung Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Non-Small Cell Lung Cancer Pipeline Drugs Market Report Overview Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. NSCLC is a cancer (malignancy) that originates in the tissues of the lungs or the cells lining the airways. Symptoms of lung cancer usually occur in the later stages of the disease. The signs and symptoms include a persistent cough that may get worse over time, trouble breathing or shortness of breath, constant chest pain or discomfort, bloody...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Sym-024
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry Sym-024 Drug Details Sym-024 is under development for the treatment of advanced or metastatic...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Sym-015
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry Sym-015 Drug Details Sym-015 is under development for the treatment of solid tumors including...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Sym-021
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry Sym-021 Drug Details Sym-021 is under development for the treatment of advanced/ unresectable or...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Sym-022
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry Sym-022 Drug Details Sym-022 is under development for the treatment of advanced/ unresectable or...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Sym-023
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry Sym-023 Drug Details Sym-023 is under development for the treatment of advanced/ unresectable or...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – (futuximab + modotuximab)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry (futuximab + modotuximab) Drug Details A fixed-dose combination of futuximab and modotuximab (Sym-004) is...
-
Product Insights
Gallbladder Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Gallbladder cancer is cancer that starts in the gallbladder. Its symptoms include abdominal pain, nausea and/or vomiting, jaundice, loss of appetite, fever, itchy skin, dark urine, and weight loss. The Gallbladder Cancer pipeline market research report provides comprehensive information on the therapeutics under development for Gallbladder Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete...